Hemocompatibility of poly(?-caprolactone) lipid-core nanocapsules stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan

详细信息    查看全文

• 作者：Eduardo A. Bender^a ; Má ; rcia D. Adorne^c ; Letí ; cia M. Colomé ; ^a ; Dulciné ; ia S.P. Abdalla^b ; Sí ; lvia S. Guterres^a ; ^d ; Adriana R. Pohlmann^a ; ^c ; ^d ; ^{pohlmann@iq.ufrgs.br}
• 关键词：Hemocompatibility ; Polymeric nanoparticles ; Lipid-core nanocapsules ; Polysorbate 80 ; Lecithin ; Chitosan
• 刊名：International Journal of Pharmaceutics
• 出版年：2012
• 出版时间：15 April, 2012
• 年：2012
• 卷：426
• 期：1-2
• 页码：271-279
• 全文大小：1048 K

文摘

The hemocompatibility of nanoparticles is of critical importance for their systemic administration as drug delivery systems. Formulations of lipid-core nanocapsules, stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan (LNC and LNC-CS), were prepared and characterized by laser diffraction (D[4,3]: 129 and 134 nm), dynamic light scattering (119 nm and 133 nm), nanoparticle tracking (D50: 124 and 139 nm) and particle mobility (zeta potential: ?5.1 mV and +9.3 mV) analysis. In vitro hemocompatibility studies were carried out with mixtures of nanocapsule suspensions in human blood at 2 % and 10 % (v/v). The prothrombin time showed no significant change independently of the nanocapsule surface potential or its concentration in plasma. Regarding the activated partial thromboplastin time, both suspensions at 2 % (v/v) in plasma did not influence the clotting time. Even though suspensions at 10 % (v/v) in plasma decreased the clotting times (p < 0.05), the values were within the normal range. The ability of plasma to activate the coagulation system was maintained after the addition of the formulations. Suspensions at 2 % (v/v) in blood showed no significant hemolysis or platelet aggregation. In conclusion, the lipid-core nanocapsules uncoated or coated with chitosan are hemocompatible representing a potential innovative nanotechnological formulation for intravenous administration.